Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precancerous Conditions 4Colorectal Neoplasms 4Breast Neoplasms 4Adenomatous Polyposis Coli 4Neoplasms 3Colonic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Unspecified Adult Solid Tumor, Protocol Specific 1Tobacco Use Disorder 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Intraductal Neoplasms 1Pain 1Melanoma 1Leukoplakia, Oral 1Leukemia, Myeloid, Acute 1Inflammation 1Hypertension 1Desmoid Tumors 1Coproporphyria 1Colonic Polyps 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Aberrant Crypt Foci 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Sulindac × Clear all
NCT00755976 2014-12-31

Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

Cancer Trials Ireland

Phase 2 Completed
32 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡